131 related articles for article (PubMed ID: 38709230)
1. Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt-Koyanagi-Harada Disease.
Guo K; Xu X; Yang F; Wang K; Zhang X
Ocul Immunol Inflamm; 2024 May; ():1-11. PubMed ID: 38709230
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
3. Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.
Vukojević M; Vukojevic N; Vuković A; Rupčić B; Blažević M; Blažević A
Acta Dermatovenerol Croat; 2023 Dec; 31(4):229-231. PubMed ID: 38651852
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy.
Yang S; Tao T; Huang Z; Liu X; Li H; Xie L; Wen F; Chi W; Su W
Front Med (Lausanne); 2021; 8():799427. PubMed ID: 35096888
[No Abstract] [Full Text] [Related]
5. Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients.
Yang S; Tao T; Li Z; Chen B; Huang Z; Liu X; Li H; Xie L; Feng W; Su W
Ann Transl Med; 2022 Jun; 10(12):699. PubMed ID: 35845536
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study.
Takeuchi M; Nakai S; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP
Saudi J Ophthalmol; 2022; 36(4):380-386. PubMed ID: 36618573
[TBL] [Abstract][Full Text] [Related]
7. Different MicroRNA profiles in Peripheral Blood mononuclear cells from patients with initial-onset and recurrent vogt-Koyanagi-Harada Disease.
Guo K; Li B; Yang F; Zhang M; Zhao G; Zhang X
Mol Biol Rep; 2022 Dec; 49(12):11421-11431. PubMed ID: 35988105
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study.
Nakai S; Takeuchi M; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP
Ocul Immunol Inflamm; 2024 May; 32(4):367-375. PubMed ID: 35748779
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
10. Ocular Inflammation and Choroidal Thickness after Pars Plana Vitrectomy in Chronic Recurrent Stage of Vogt-Koyanagi-Harada Disease.
Park UC; Yu HG
Ocul Immunol Inflamm; 2021 Feb; 29(2):388-395. PubMed ID: 31671005
[No Abstract] [Full Text] [Related]
11. Decrease of choriocapillary vascular density measured by optical coherence tomography angiography in Vogt-Koyanagi-Harada disease.
Liang A; Jia S; Gao F; Han X; Pei M; Qu Y; Xiao J; Zhao C; Zhang M
Graefes Arch Clin Exp Ophthalmol; 2021 Nov; 259(11):3395-3404. PubMed ID: 34216256
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
13. Incidence, Risk Factors and Surgical Outcomes of Cataract among Patients with Vogt-Koyanagi-Harada Disease.
AlBloushi AF; Alfawaz AM; AlZaid A; Alsalamah AK; Gikandi PW; Abu El-Asrar AM
Ocul Immunol Inflamm; 2021 Jan; 29(1):128-136. PubMed ID: 31638886
[No Abstract] [Full Text] [Related]
14. Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome.
Jeroudi A; Angeles-Han ST; Yeh S
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(4):332-4. PubMed ID: 25037015
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy.
Alromaih AZ; Almater AI; Albloushi AF; Alkheraiji NF; Abu El-Asrar AM
Int Ophthalmol; 2023 Jan; 43(1):185-195. PubMed ID: 35945413
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.
Rahman N; Artiaga JCM; Bouras K; Luis J; Rees A; Westcott M
J Ophthalmic Inflamm Infect; 2023 May; 13(1):27. PubMed ID: 37204477
[TBL] [Abstract][Full Text] [Related]
17. Treatment and Prognosis of Vogt-Koyanagi-Harada Disease: Real-Life Experience in Long-Term Follow-Up.
Accorinti M; Saturno MC; Iannetti L; Manni P; Mastromarino D; Pirraglia MP
J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806916
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy.
Takayama K; Obata H; Takeuchi M
Ocul Immunol Inflamm; 2020 Apr; 28(3):509-512. PubMed ID: 31268769
[No Abstract] [Full Text] [Related]
19. Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease.
Herbort CP; Abu El Asrar AM; Takeuchi M; Pavésio CE; Couto C; Hedayatfar A; Maruyama K; Rao X; Silpa-Archa S; Somkijrungroj T
Int Ophthalmol; 2019 Jun; 39(6):1419-1425. PubMed ID: 29948499
[TBL] [Abstract][Full Text] [Related]
20. Choroidal observations in Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography.
Nakai K; Gomi F; Ikuno Y; Yasuno Y; Nouchi T; Ohguro N; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2012 Jul; 250(7):1089-95. PubMed ID: 22240936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]